High rate of complete remission and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant in patients with multiple myeloma. Results of a phase II prospective study

被引：0
|
作者：
Sahebi, F. [1 ]
Krishnan, A. [1 ]
Farol, L. [1 ]
Cai, J. -L. [1 ]
Somlo, G. [1 ]
Popplewell, L. [1 ]
Parker, P. [1 ]
Spielberger, R. [1 ]
Kogut, N. [1 ]
Karanes, C. [1 ]
Ruel, C. [1 ]
Frankel, P. [1 ]
Reburiano, E. [1 ]
Duarte, L. [1 ]
O'Donnell, L. [1 ]
Forman, S. [1 ]
机构：
[1] City Hope Med Ctr, Duarte, CA USA
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [1] High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients With Multiple Myeloma. Results of a Phase II Prospective Study
    Sahebi, Firoozeh
    Krishnan, Amrita
    Farol, Leonardo
    Cai, Ji-Lian
    Somlo, George
    Popplewell, Leslie
    Spielberger, R.
    Kogut, Neil Martin
    Karanes, Chatchada
    Ruel, Christopher
    Frankel, Paul
    Reburiano, Eunicia
    O'Donnell, Margret
    Forman, Stephen
    BLOOD, 2010, 116 (21) : 994 - 995
  • [2] Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant
    Jimenez-Zepeda, Victor H.
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Murray, Karen
    Culham, Marcia
    Luider, Joanne
    Fourie, Thomas
    Rashid-Kolvear, Fariborz
    Bahlis, Nizar J.
    LEUKEMIA & LYMPHOMA, 2016, 57 (04) : 973 - 976
  • [3] REMISSION DURATION AND QUALITY OF RESPONSE IMPROVEMENT IN ADULT MULTIPLE MYELOMA PATIENTS WITH BORTEZOMIB MAINTENANCE POST AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
    Norata, M.
    Bongarzoni, V.
    Greco, R.
    Pauselli, F.
    Anaclerico, B.
    Borza, P. Anticoli
    Cedrone, M.
    Chierichini, A.
    Coppola, I.
    Fenu, S.
    Ronci, B.
    Cortese, S.
    Bruno, R.
    Annino, L.
    HAEMATOLOGICA, 2012, 97 : 627 - 627
  • [4] A phase II study of sequential velcade/thalidomide/dexamethasone as maintenance therapy post single autologous peripheral stem cell in patients with multiple myeloma
    Sahebi, F.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S148 - S148
  • [5] Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Thomas, Sheeba K.
    Shah, Jatin J.
    Lee, Hans C.
    Manasanch, Elisabet E.
    Weber, Donna M.
    Patel, Krina K.
    Feng, Lei
    Amini, Behrang
    Morphey, Ashley
    Crumpton, Brandon
    Phillips, Suzanne
    Miller, Carla
    Gonzalez, Mariann
    Orlowski, Robert Z.
    BLOOD, 2017, 130
  • [6] Early immumoglobulin free light chain (FLC) response post autologous peripheral blood stem cell transplant predicts for hematologic complete response in patients with multiple myeloma.
    Dispenzieri, Angela
    Vincent Rajkumar, S.
    Plevak, Matthew F.
    Katzmann, Jerry A.
    Kyle, Robert A.
    Larson, Dirk
    Lacy, Martha Q.
    Clark, Raynell
    DeGoey, Roberta
    Hayman, Suzanne R.
    Kumar, Shaji K.
    Gertz, Morie Abraham
    BLOOD, 2006, 108 (11) : 883A - 883A
  • [7] Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma
    Shah, Jatin J.
    Baladandayuthapani, Veera
    Weber, Donna M.
    Thomas, Sheeba K.
    Alexanian, Raymond
    Wang, Michael
    Qazilbash, Muzaffar H.
    Champlin, Richard E.
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Nieto, Yago
    Ahmed, Sairah
    Parmar, Simrit
    Orlowski, Robert Z.
    BLOOD, 2013, 122 (21)
  • [8] Phase II Study of Iberdomide Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma: Results of a Planned Interim Analysis
    Wildes, Tanya
    Suman, Vera Jean
    Strege, Marnee
    Tario, Joseph
    Holstein, Sarah
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S32 - S32
  • [9] A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
    Rifkin, Robert M.
    Greenspan, Andrew
    Schwerkoske, John F.
    Mandanas, Romeo A.
    Stephenson, Joe J.
    Kannarkat, George T.
    Zhan, Feng
    Boehm, Kristi A.
    Asmar, Lina
    Beveridge, Roy
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 714 - 722
  • [10] A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
    Robert M. Rifkin
    Andrew Greenspan
    John F. Schwerkoske
    Romeo A. Mandanas
    Joe J. Stephenson
    George T. Kannarkat
    Feng Zhan
    Kristi A. Boehm
    Lina Asmar
    Roy Beveridge
    Investigational New Drugs, 2012, 30 : 714 - 722
12345